Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliations: London School of Hygiene and Tropical Medicine, London, England (Dr Yates; firstname.lastname@example.org). Dr Sonnabend is retired.
To the Editor: While the Strategic Timing of Antiretroviral Treatment (START)1 and other trials are being conducted, decisions on the initiation of antiretroviral treatment at higher CD4 cell counts must rest on complex observational evidence. Without randomization, individuals who initiate treatment early may be systematically different from those who initiate treatment later. We are concerned that publication of the recent update to the International Antiviral (formerly AIDS) Society–USA (IAS-USA) Panel's recommendations2 may slow recruitment to ongoing randomized controlled trials by suggesting there is no longer equipoise.
Yates TA, Sonnabend J. Treatment of Human Immunodeficiency Virus in Adults. JAMA. 2012;308(15):1522–1523. doi:10.1001/jama.2012.12886
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: